Glucose Monitoring Devices Market Growth Accelerating with Rising Prevalence of Diabetes Globally | FMI

 According to Future Market Insights' most recent industry report, the global Glucose Monitoring Devices Market was valued at roughly US$ 21.3 Billion in 2022 and is expected to rise at a CAGR close to 16.9% over the forecast period, reaching an estimated worth of US$ 118.1 Billion in 2033.

Over the past 20 years, diabetes has escalated to a severe health concern with an unparalleled rate of global growth. It is a significant contributor to death in those aged 20 to 79. The World Health Organization has classified diabetes as a global pandemic due to its rapidly increasing prevalence.

For more information: https://www.futuremarketinsights.com/reports/glucose-monitoring-devices-market

Patients with diabetes require regular monitoring. Costs associated with patient monitoring can be decreased by utilizing technologies for information and communication, artificial intelligence, and smart devices together. Diabetes is mostly brought on by changes in blood glucose levels, and it is important to keep them steady for a set period.


The adoption of continuous glucose monitoring devices, which are emerging as a novel technique for monitoring glucose levels, is growing along with the number of diabetic patients. Every ten minutes, these devices update the real-time glucose level data they provide. The preservation of healthy blood glucose level is the only method for a diabetic to prevent potentially fatal diabetic complications, and glucose monitoring is an essential component of diabetes management.

Non-invasive glucose monitoring has recently become more popular as it lessens the discomfort and suffering experienced by diabetics who must prick their skin more than four times per day to measure their blood glucose levels.

With increasing prevalence of diabetes, as well as advancements in sensor-based technologies for patient monitoring, the market is set to expand at a lucrative pace, over the forecast period.

Key Takeaways from Market Study

  • Self-monitoring devices are the leading segment as product, and hold approximately 3% market value share in 2022, owing to their automated and reliable monitoring process.
  • Diabetes type II segment is set to lead in terms of indication of Diabetes monitoring systems with an estimated market value share of around 1% by 2023, owing to the high prevalence of type II diabetes globally.
  • By end user, hospitals held a market share of around 7% in 2022, owed to the adoption of continuous monitoring devices in hospitals to reduce the number of fingerstick point of care capillary blood glucose tests, hyperglycemic episodes, and hypoglycemic episodes.
  • North America holds a value share of 0% in 2022, owing to the high prevalence of chronic diseases in the region.

“Rising initiatives to integrate artificial intelligence, as well as digital technologies to blood glucose monitoring devices, as well as growing new product launch activities, are factors propelling the growth of the global glucose monitoring market,” says an analyst of Future Market Insights.

Market Competition

Key players' rigorous research led to the development of improved technologies such as flash glucose monitoring and continuous glucose monitoring. Companies also engage in strategic initiatives such as new product launches and mergers and acquisitions.

  • All consumers with diabetes type 1 are now covered for the Dexcom G6 rtCGM System under the Non-Insured Health Benefits Program, according to an announcement made by Dexcom, Inc. in January 2023.
  • Abbott disclosed in June 2022 that it is creating a new biowearable that combines a sensor to continually monitor both glucose and ketone levels. The U.S. FDA has granted the system breakthrough device classification.

Key Companies Profiled:

  • Dexcom, Inc.
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Medtronic
  • Ascensia Diabetes Care
  • Arkray
  • Ypsomed AG
  • Acon Laboratories
  • Nipro
  • Nova Biomedical
  • Goldsite Diagnostics Inc. (China)
  • Lifescan Ip Holdings, LLC
  • Prodigy Diabetes Care
  • Others

Key Market Segments Covered in Glucose Monitoring Devices Industry Research

Product:

  • Self-Monitoring Devices
  • Continuous Monitoring Devices

Indication:

  • Diabetes Type I
  • Diabetes Type II

End User:

  • Hospitals
  • Clinics
  • Diagnostics Centres
  • Home Care Settings

Comments

Post a Comment

Popular posts from this blog

Pet Diabetes Care Devices Market Report | Size, Growth, Demand, Scope and Forecast to 2032

  The global  Pet Diabetes Care Devices Market  is expected to grow at a  6.5%  CAGR, reaching  US$ 4 billion  by 2032, up from  US$ 2 billion  in 2021. “The number of pets with diabetes, the number of adopted pets, and the number of overweight pets are all driving the market forward.” Get Full Access @ https://www.futuremarketinsights.com/reports/pet-diabetes-care-devices-market The domestication of animals is leading to a lack of insulin production in them. The limited flow of glucose to the cell can be termed diabetes. This chronic disease is a major concern for pet owners and needs to be taken care of. This concern leads to the expansion of the pet diabetes care devices market. Devices like the alphatrak blood glucose meter are in use as they help the pet owners monitor the pet’s health. The increased number of people adopting pets and then domesticating them around in their households, treating and caring for them as f...
Read more

Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

Image
  The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million...
Read more

Clostridium Diagnostics Market in US is anticipated to secure a market value worth US$ 2.7 Billion by 2032 | FMI

Image
  The global Clostridium Diagnostics Market is expected to grow at a CAGR of 12.2% during the forecast period, from US$ 2.5 billion in 2022 to US$ 7.8 billion by 2032. The market grew at a CAGR of 13.6% between 2015 and 2021. The rising prevalence of clostridium-related diseases, as well as increased campaigns to educate people about the condition, are driving the market growth. To learn more about this report @ https://www.futuremarketinsights.com/reports/clostridium-diagnostics-market here has been an increased focus of players in the market to offer vaccines, which can augment the market size in the forecast period. For instance, in March 2022, Japan launched a new center, with a budget of US$ 1.6 Billion, to support vaccine and drug projects as a part of a larger scheme to tackle infectious diseases. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects. Awareness camp...
Read more